Anticancer Drugs Market: Snapshot

One of the leading causes of death is cardiovascular diseases followed by cancer. It is estimated that 1 out of 6 deaths is caused due to cancer. Within 3 years of the discovery of cancer its antidrug was invented hence proving that medical science has made enormous advances. On account of the growing demand for cancer curing drugs worldwide, the pharmaceuticals market, especially with regard to anti-cancer drugs is on hike.

global-anticancer-drugs-market.jpgThe Global market for anticancer drugs comprises of a highly aggressive vendor landscape. In view of a number of the largest leading pharmaceutical players of the world, the market is fragmented. The leading companies compete with innovative products and strong pipelines to boast the high efficacy and efficiency in the market. There is also a constant rise in the number of small players as they are focusing on innovative treatment methods.

The global anticancer drugs market is estimated to expand to US$155.6 BN by 2025 with a 6-7% CAGR within the forecast period of 2017 to 2025. The previous market value of 2015 was at US$ 85.0 bn in 2016.

Anti-cancer drugs with minimum Side-effects driving growth in the market

Based on therapy, the anticancer drug market is segmented into immunotherapy, targeted therapy and chemotherapy. Immunotherapy is usually for treating melanoma, a dangerous form of skin cancer. The segment for targeted drugs accounts for more than 40% of share value in the global drugs market for anti-cancer. As compared to cytotoxic drugs, minimum side effects along with effective results and high specificity of the drugs are predicted to expand the growth of the segment by 2025.

 On the basis of cancer type, there is colorectal cancer, breast cancer, leukemia and lung cancer out of which lung cancer is predicted to expand at a strong CAGR of over 6% due to large number of lung cancer incidences and high prevalence and promising pipeline for non-small cell lung cancer (NSCLC) drugs during the forecast period.

North America to Contribute Large Share in Future with Private and Public Sector Support

The global anticancer drugs market is studied on the basis of key geographies Middle East and Africa, Latin America, Asia Pacific, Europe, and North America. Among these, Germany, U.K. and U.S. show higher adoption for anti-cancer drugs compared to other regions. This is because of the prevalence of unhealthy lifestyle, developed healthcare infrastructure, targeted efforts of government and NGOs towards cancer management.

North America is expected to grow at a rapid pace during the forecast period other than Japan and Australia which seems favorable for the market growth. Increased awareness regarding the benefits of early diagnosis, rising disposable incomes, rising prevalence of number of forms of cancer, and projected pipeline drugs are propelling the growth of the regional market. Due to the easy availability of drugs in the region, and high healthcare expenditure from both the private and public sector, North America is predicted to contribute largely to the anticancer drugs market globally. Apart from that, established players are entering China and India due to high prevalence making the market attractive. The markets in other regions such as Africa, Middle East and Latin America are expected to grow during the forecast period at moderate rate.

In the global anticancer drugs market, companies like Amgen Inc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd are the key players.

Endorsements from Provincial Administrative Bodies will Boost Anticancer Drugs Market

The increasing number of deaths caused due to cancer is a prime factor augmenting the growth of the global anticancer drugs market. Cancer is a gathering of sicknesses related with strange cell development with the possibility to torment or spread to different pieces of the body. Significant sorts of tumors incorporate carcinomas, sarcomas, lymphomas, and leukemia. Sarcomas start in the connective tissue like muscle or bones. Delicate tissue sarcomas can start in greasy tissues. Additionally, the therapy of malignancy in patients requires the utilization of various drugs like hormonal treatment, immunotherapy, directed treatment, and others.

Moreover, natural drugs based on monoclonal antibodies (mAbs) have arisen as a favored alternative to treat different malignancy types, particularly blood disease (leukemia). Ascend in frequency of different disease conditions, expansion in ubiquity of advance treatments (organic and focused on drug treatments), and flood in geriatric populace overall are the key components driving the development of the worldwide oncology/malignancy drugs market. Moreover, ascend in malignancy mindfulness and accessibility of disease drugs are required to support the market development.

The development of the worldwide oncology/malignancy drugs market is significantly determined by expansion in rate of different disease conditions, ascend in ubiquity of advance treatments (natural and focused on drug treatments), and flood in geriatric populace around the world. Moreover, ascend in disease mindfulness and accessibility of malignancy drugs are required to help the market development. In any case, significant expense engaged with new medication advancement combined with danger of disappointment and unfriendly impacts related with malignancy drugs treatments is required to control the development of the market. Then again, high capability of arising economies and expansion in number of pipeline items are required to give new freedoms to advertise major parts in future.

On the contrary, high cost of therapies and severe unofficial laws are required to control the worldwide enemy of malignant growth drug market later on. Drug associations face difficulties in recuperating the immense expense engaged with new item advancement. These drugs have a danger of results which are required to hamper in general item interest in the coming years.

Nevertheless, drug associations are focusing on creating new medications to address buyer issues. Medication endorsement from provincial administrative bodies is a significant development factor and in this way support from the local government bodies and non-benefit associations is relied upon to drive worldwide enemy of disease drug market interest over the estimate time frame.

Global Anticancer drugs Market: Scope and Research Methodology

This report on the global anticancer drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of features of different type of drugs, therapies and cancer types. Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Anticancer drugs Market: Segmentation

Cancer is caused due to abnormal growth of the cells. Anticancer drugs are also known as antineoplastic drugs. These drugs prevents and inhibits the growth of cancer cells.

Based on drug types, global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. The targeted drugs segment is further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others. The segment is anticipated to hold a significant share of the global market. The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.

Based on therapy type, global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period. Side effects of chemotherapy and specificity of the targeted drug are the factors driving the growth of global market.

Based on cancer types, the global anticancer drugs market is segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others. The lung cancer segment is expected to expand at the fast rate due to high prevalence of the disease worldwide.

Anticancer drugs Market: Geographical and Competitive Dynamics

Geographically, the global anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global anticancer drugs market has been segmented as follows:

Drug Type

  • Cytotoxic Drugs
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Targeted Drugs
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitors
    • Others
  • Hormonal Drugs

Therapy Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Leukemia
  • Colorectal Cancer
  • Others

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & NZ
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anticancer Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Drug Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunity
            4.3.4. Trends
     4.4. Global Anticancer Drugs Market Analysis and Forecasts, 2015-2025
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis
     4.6. Value Chain Analysis
     4.7. Market Outlook
     4.8. Pipeline Analysis
     4.9. Disease Overview
     4.10. Evolution of Cancer Therapies

5. Global Anticancer Drugs Market Analysis and Forecasts, By Drug Type 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Market Value Forecast By Drug Type , 2015-2025
            5.3.1. Cytotoxic Drugs
                     5.3.1.1. Alkylating Agents
                     5.3.1.2. Antimetabolites
                     5.3.1.3. Others
            5.3.2. Targeted Drugs
                     5.3.2.1. Monoclonal Antibodies
                     5.3.2.2. Tyrosine Kinase Inhibitors
                     5.3.2.3. Others
            5.3.3. Hormonal Drugs
     5.4. Market Attractiveness By Drug Type 

6. Global Anticancer Drugs Market Analysis and Forecasts, By Therapy Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast By Therapy Type , 2015-2025
            6.3.1. Chemotherapy
            6.3.2. Targeted Therapy
            6.3.3. Immunotherapy
            6.3.4. Others
     6.4. Market Attractiveness By Therapy Type 

7. Global Anticancer Drugs Market Analysis and Forecasts, By Cancer Type 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast By Cancer Type , 2015-2025
            7.3.1. Lung Cancer
            7.3.2. Breast Cancer
            7.3.3. Leukemia
            7.3.4. Colorectal Cancer
            7.3.5. Others
     7.4. Market Attractiveness By Cancer Type 

8. Global Anticancer Drugs Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Market Value Forecast By Region
            8.2.1. North America 
            8.2.2. Europe 
            8.2.3. Asia Pacific 
            8.2.4. Latin America 
            8.2.5. Middle East & Africa 
     8.3. Market Attractiveness By Region

9. North America Anticancer Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Key Trends
     9.2. Market Value Forecast By Drug Type , 2015-2025
            9.2.1. Cytotoxic Drugs
                     9.2.1.1. Alkylating Agents
                     9.2.1.2. Antimetabolites
                     9.2.1.3. Others
            9.2.2. Targeted Drugs
                     9.2.2.1. Monoclonal Antibodies
                     9.2.2.2. Tyrosine Kinase Inhibitors
                     9.2.2.3. Others
            9.2.3. Hormonal Drugs
     9.3. Market Value Forecast By Therapy Type , 2015-2025
            9.3.1. Chemotherapy
            9.3.2. Targeted Therapy
            9.3.3. Immunotherapy
            9.3.4. Others
     9.4. Market Value Forecast By Cancer Type , 2015-2025
            9.4.1. Lung Cancer
            9.4.2. Breast Cancer
            9.4.3. Leukemia
            9.4.4. Colorectal Cancer
            9.4.5. Others
     9.5. Market Value Forecast By Country, 2015-2025
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Drug Type 
            9.6.2. By Therapy Type 
            9.6.3. By Cancer Type 
            9.6.4. By Country

10. Europe Anticancer Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Key Trends
     10.2. Market Value Forecast By Drug Type , 2015-2025
            10.2.1. Cytotoxic Drugs
                     10.2.1.1. Alkylating Agents
                     10.2.1.2. Antimetabolites
                     10.2.1.3. Others
            10.2.2. Targeted Drugs
                     10.2.2.1. Monoclonal Antibodies
                     10.2.2.2. Tyrosine Kinase Inhibitors
                     10.2.2.3. Others
            10.2.3. Hormonal Drugs
     10.3. Market Value Forecast By Therapy Type , 2015-2025
            10.3.1. Chemotherapy
            10.3.2. Targeted Therapy
            10.3.3. Immunotherapy
            10.3.4. Others
     10.4. Market Value Forecast By Cancer Type , 2015-2025
            10.4.1. Lung Cancer
            10.4.2. Breast Cancer
            10.4.3. Leukemia
            10.4.4. Colorectal Cancer
            10.4.5. Others
     10.5. Market Value Forecast By Country / Sub-region, 2015-2025
            10.5.1. U.K. 
            10.5.2. Germany
            10.5.3. France
            10.5.4. Italy 
            10.5.5. Spain 
            10.5.6. Rest of Europe
     10.6. Market Attractiveness Analysis 
            10.6.1. By Drug Type 
            10.6.2. By Therapy Type 
            10.6.3. By Cancer Type 
            10.6.4. By Country / Sub-region

11. Asia Pacific Anticancer Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Key Trends
     11.2. Market Value Forecast By Drug Type , 2015-2025
            11.2.1. Cytotoxic Drugs
                     11.2.1.1. Alkylating Agents
                     11.2.1.2. Antimetabolites
                     11.2.1.3. Others
            11.2.2. Targeted Drugs
                     11.2.2.1. Monoclonal Antibodies
                     11.2.2.2. Tyrosine Kinase Inhibitors
                     11.2.2.3. Others
            11.2.3. Hormonal Drugs
     11.3. Market Value Forecast By Therapy Type , 2015-2025
            11.3.1. Chemotherapy
            11.3.2. Targeted Therapy
            11.3.3. Immunotherapy
            11.3.4. Others
     11.4. Market Value Forecast By Cancer Type , 2015-2025
            11.4.1. Lung Cancer
            11.4.2. Breast Cancer
            11.4.3. Leukemia
            11.4.4. Colorectal Cancer
            11.4.5. Others
     11.5. Market Value Forecast By Country / Sub-region, 2015-2025
            11.5.1. China
            11.5.2. Japan
            11.5.3. India
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis 
            11.6.1. By Drug Type 
            11.6.2. By Therapy Type 
            11.6.3. By Cancer Type 
            11.6.4. By Country / Sub-region

12. Latin America Anticancer Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Key Trends
     12.2. Market Value Forecast By Drug Type , 2015-2025
            12.2.1. Cytotoxic Drugs
                     12.2.1.1. Alkylating Agents
                     12.2.1.2. Antimetabolites
                     12.2.1.3. Others
            12.2.2. Targeted Drugs
                     12.2.2.1. Monoclonal Antibodies
                     12.2.2.2. Tyrosine Kinase Inhibitors
                     12.2.2.3. Others
            12.2.3. Hormonal Drugs
     12.3. Market Value Forecast By Therapy Type , 2015-2025
            12.3.1. Chemotherapy
            12.3.2. Targeted Therapy
            12.3.3. Immunotherapy
            12.3.4. Others
     12.4. Market Value Forecast By Cancer Type , 2015-2025
            12.4.1. Lung Cancer
            12.4.2. Breast Cancer
            12.4.3. Leukemia
            12.4.4. Colorectal Cancer
            12.4.5. Others
     12.5. Market Value Forecast By Country / Sub-region, 2015-2025
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis 
            12.6.1. By Drug Type 
            12.6.2. By Therapy Type 
            12.6.3. By Cancer Type 
            12.6.4. By Country / Sub-region

13. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Key Trends
     13.2. Market Value Forecast By Drug Type , 2015-2025
            13.2.1. Cytotoxic Drugs
                     13.2.1.1. Alkylating Agents
                     13.2.1.2. Antimetabolites
                     13.2.1.3. Others
            13.2.2. Targeted Drugs
                     13.2.2.1. Monoclonal Antibodies
                     13.2.2.2. Tyrosine Kinase Inhibitors
                     13.2.2.3. Others
            13.2.3. Hormonal Drugs
     13.3. Market Value Forecast By Therapy Type , 2015-2025
            13.3.1. Chemotherapy
            13.3.2. Targeted Therapy
            13.3.3. Immunotherapy
            13.3.4. Others
     13.4. Market Value Forecast By Cancer Type , 2015-2025
            13.4.1. Lung Cancer
            13.4.2. Breast Cancer
            13.4.3. Leukemia
            13.4.4. Colorectal Cancer
            13.4.5. Others
     13.5. Market Value Forecast By Country / Sub-region, 2015-2025
            13.5.1. GCC Countries
            13.5.2. South Africa
            13.5.3. Rest of MEA
     13.6. Market Attractiveness Analysis 
            13.6.1. By Drug Type 
            13.6.2. By Therapy Type 
            13.6.3. By Cancer Type 
            13.6.4. By Country / Sub-region

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Market Share Analysis By Company (2016)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. F. Hoffmann-La Roche Ltd
                     14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.1.2. Product Portfolio
                     14.3.1.3. SWOT Analysis
                     14.3.1.4. Financial Overview
                     14.3.1.5. Strategic Overview
            14.3.2. Eli Lilly and Company
                     14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.2.2. Product Portfolio
                     14.3.2.3. SWOT Analysis
                     14.3.2.4. Financial Overview
                     14.3.2.5. Strategic Overview
            14.3.3. Novartis AG
                     14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.3.2. Product Portfolio
                     14.3.3.3. SWOT Analysis
                     14.3.3.4. Financial Overview
                     14.3.3.5. Strategic Overview
            14.3.4. Pfizer Inc
                     14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.4.2. Product Portfolio
                     14.3.4.3. SWOT Analysis
                     14.3.4.4. Financial Overview
                     14.3.4.5. Strategic Overview
            14.3.5. Bayer AG
                     14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.5.2. Product Portfolio
                     14.3.5.3. SWOT Analysis
                     14.3.5.4. Financial Overview
                     14.3.5.5. Strategic Overview
            14.3.6. AstraZeneca
                     14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.6.2. Product Portfolio
                     14.3.6.3. SWOT Analysis
                     14.3.6.4. Financial Overview
                     14.3.1.5. Strategic Overview
            14.3.7. Takeda Pharmaceutical Company Limited
                     14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.7.2. Product Portfolio
                     14.3.7.3. SWOT Analysis
                     14.3.7.4. Financial Overview
                     14.3.7.5. Strategic Overview
            14.3.8. Merck & Co., Inc.
                     14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.8.2. Product Portfolio
                     14.3.8.3. SWOT Analysis
                     14.3.8.4. Financial Overview
                     14.3.8.5. Strategic Overview
            14.3.9. CELGENE CORPORATION
                     14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.9.2. Product Portfolio
                     14.3.9.3. SWOT Analysis
                     14.3.9.4. Financial Overview
                     14.3.9.5. Strategic Overview
            14.3.10. Amgen Inc
                     14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.10.2. Product Portfolio
                     14.3.10.3. SWOT Analysis
                     14.3.10.4. Financial Overview
                     14.3.10.5. Strategic Overview

List of Tables

Table 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, By Phase II and Phase I
Table 03: Pipeline Analysis, By Preclinical Trial (1/2)
Table 04: Pipeline Analysis, By Preclinical Trial (2/2)
Table 05: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 06: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 2015–2025
Table 07: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Targeted Drugs, 2015–2025
Table 08: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type, 2015–2025
Table 09: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2015–2025
Table 10: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 12: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 13: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 14: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 15: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 16: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 17: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 18: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 19: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 20: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 21: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 22: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 23: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 24: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 25: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 26: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 27: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 28: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 29: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 30: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 31: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 32: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 33: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 34: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 35: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 36: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 37: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 38: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 39: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 40: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025

List of Figures

Figure 01: Global Anticancer Drugs Market, by Drug Type, Market Size (US$ Mn), 2016 (A)
Figure 02:  Global Anticancer Drugs Market Revenue (%), by Cancer Therapy, 2016 (A)
Figure 03:  Global Anticancer Drugs Market Revenue (%), by Region, 2016 (A)
Figure 04: Opportunity Map, By Drug Type 2016
Figure 05: Opportunity Map, By Therapy type and Cancer Type 2016
Figure 06: Global Anticancer Drugs Market - Key Industry Developments
Figure 07: Global Anticancer Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 08: Porter’s Five Forces Analysis
Figure 09: Global Anticancer Drugs Market - Value Chain Analysis
Figure 10: Market Value Share, by Drug Type (2016)
Figure 11: Market Value Share, by Therapy Type (2016)
Figure 12: Market Value Share, by Cancer Types (2016)
Figure 13: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 14: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cytotoxic Drugs, 2015–2025
Figure 15: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Drugs, 2015–2025
Figure 16: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hormonal Drugs, 2015–2025
Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 18: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 19: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy, 2015–2025
Figure 20: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2015–2025
Figure 21: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2015–2025
Figure 22: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2015–2025
Figure 23: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type 
Figure 24: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 25: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Lung Cancer, 2015–2025
Figure 26: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Breast Cancer, 2015–2025
Figure 27: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Leukemia, 2015–2025
Figure 28: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Colorectal Cancer, 2015–2025
Figure 29: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 30: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2017–2025
Figure 31: Global Scenario of Anticancer Drugs Market 
Figure 32: Global Anticancer Drugs Market Value Share Analysis, by Region, 2016 and 2025
Figure 33: Global Anticancer Drugs Market Attractiveness Analysis, by Region
Figure 34: North America Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 35: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 36: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 37: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 38: North America Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 39: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 40: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 41: North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 42: North America Market Attractiveness Analysis, by Country
Figure 43: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 44: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 45: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 46: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 47: Europe Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 48: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 49: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 50: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 51: Europe Market Attractiveness Analysis, by Country
Figure 52: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 53: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 54: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 55: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 56: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 57: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 58: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 59: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 60:Asia Pacific Market Attractiveness Analysis, by Country
Figure 61: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 62: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 63: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 64: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 65: Latin America Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 66: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 67: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 68: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 69: Latin America Market Attractiveness Analysis, by Country
Figure 70: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 71: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 72: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 73: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 74: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 75: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 76: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 77: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 78: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 79: Global  Anticancer Drugs Market Share Analysis, by Company (2016)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Anticancer Drugs Market